Drug Approval | August 07, 2025
Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg
This is the group’s first NoC approval in Canada
This is the group’s first NoC approval in Canada
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Jadhav has completed his B.Pharmacy and is having 30+ years of rich experience in operation management in pharmaceutical Industry
No safety signals related to the vaccine candidate were identified
Plans underway to expand screening capacity by 50% for greater accessibility
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
